Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo (matched to Pregabalin) Clear all
Completed Phase 3 Interventional Results available

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

NCT00468845
View directory record Official record
Conditions
Pain, Postoperative
Interventions
pregabalin (Lyrica), matched placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
25 Years to 70 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
14
States / cities
Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Trial of Pregabalin (Lyrica) for Irritable Bowel Syndrome

NCT00977197
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 27, 2026, 6:43 PM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

NCT06628908
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
Suzetrigine, Placebo (matched to SUZ), Pregabalin, Placebo (matched to Pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
76
States / cities
Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

NCT05660538
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
50
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

NCT00729690
View directory record Official record
Conditions
PAIN
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
55 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)

NCT01688947
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
V116517 50-mg tablets, V116517 30-mg tablets, Pregabalin capsules, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
21 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
28
States / cities
Tucson, Arizona • La Jolla, California • North Hollywood, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability

NCT01928381
View directory record Official record
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Interventions
AZD5213 + pregabalin, Placebo, pregabalin capsules
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Clearwater, Florida • Orlando, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2016 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

NCT02215252
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
PF-05089771 150 mg, Matched placebo for PF-05089771 150 mg and pregabalin 300 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
32
States / cities
Phoenix, Arizona • Fresno, California • Bradenton, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

NCT00407745
View directory record Official record
Conditions
Neuralgia, Spinal Cord Injuries
Interventions
placebo, pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Fresno, California • Napa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 27, 2026, 6:43 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Pregabalin for Granulocyte Colony-stimulating Factor (GCSF)-Induced Bone Pain

NCT03407430
View directory record Official record
Conditions
Breast Cancer, Lymphoma, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Duloxetine Versus Pregabalin for Alcohol Dependence

NCT00929344
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Pregabalin, Duloxetine, Standardized behavioral therapy, Placebo
Drug · Behavioral
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional

Diabetic Peripheral Neuropathic Pain (DPNP)

NCT01314222
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
BMS-954561, Pregabalin, Placebo matching BMS-954561, Placebo matching Pregabalin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • Lomita, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 3 Interventional Results available

Once-A-Day Pregabalin For Partial Seizures

NCT01262677
View directory record Official record
Conditions
Partial Seizures, Epilepsies, Partial
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Northport, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 2 Interventional Results available

Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves

NCT01939366
View directory record Official record
Conditions
Chronic Pain, Diabetic Neuropathies, Diabetes Mellitus
Interventions
Cebranopadol 100 µg, Cebranopadol 300 µg, Cebranopadol 600 µg, Pregabalin, Matching Placebo
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
Mesa, Arizona • Garden Grove, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 27, 2026, 6:43 PM EDT
Recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

NCT06619860
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
VX-993, Pregabalin, Placebo (matched to pregabalin), Placebo (matched to VX-993)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Cullman, Alabama • Bakersfield, California • La Mesa, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Results available

Prophylactic Pregabalin to Decrease Pain During Medical Abortion

NCT02782169
View directory record Official record
Conditions
Acute Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 27, 2026, 6:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Not applicable Interventional Results available

Pregabalin in CIPN

NCT02394951
View directory record Official record
Conditions
Neuropathy, Pain
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2019 · Synced Sep 27, 2026, 6:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI of Anxiolytic Medications (Pregabalin)

NCT00706836
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Pregabalin 50mg, Pregabalin 200 MG, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 27, 2026, 6:43 PM EDT